To identify dysregulated pathways in distinct phases of NOTCH1-mediated T-cell leukemogenesis, as well as small-molecule inhibitors that could synergize with or substitute for gamma-secretase
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) results from a number of transformative steps that involve molecular abnormalities in transcription factor genes. 1, 2 Translocations that juxtapose TCR gene sequences with TAL1, LMO1, HOX11 or other transcriptional factors occur in 35% of T-ALL cases. [1] [2] [3] Independent of these molecular events, mutations or translocations that lead to aberrant NOTCH1 activation are a common occurrence in T-ALL, [4] [5] [6] and are likely to involve a number of signaling pathways that control T-cell growth and proliferation. Overexpression of the activated form of NOTCH1 in hematopoietic cells causes T-cell neoplasms in both mice and zebrafish, 7-9 providing animal models to investigate mechanisms of transformation. Targeting of the NOTCH1 protein with small-molecule γ-secretase inhibitors (GSIs) blocks the growth of T-ALL cells, 4, 10 indicating that NOTCH1 signaling is required not only for transformation, but also for the continuous growth of affected T-lymphoblasts.
The transcriptional targets of NOTCH1 in T-ALL have been reported by us and others.
11-15
One of the direct targets most relevant to NOTCH1-dependent T-ALL cell growth is the MYC oncogene.
11-13
In GSI-sensitive T-ALL cell lines, overexpression of MYC rescues the growth inhibition imposed by GSI, while GSI-resistant T-ALL cell lines fail to downregulate MYC after GSI treatment, indicating that MYC plays a critical role in the pathogenesis of T-ALL; however, overexpression of MYC by itself is not sufficient to induce T-ALL, with additional events required to initiate clonal growth of leukemic cells. 16, 17 In this regard, retroviral insertional mutagenesis identified overexpression of truncated and full-length NOTCH1 as a frequent collaborating lesion in MYC-induced T-ALL. 16 We therefore hypothesize that signaling pathways driven by NOTCH1,
MYC and other complementary molecules interact synergistically to promote transformation to
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We recently reported that overexpression of intracellular Notch1 (ICN1) , an activated form of Notch1, in transplanted Lin-negative murine hematopoietic cells, leads to T-ALL. model; however, the roles of other collaborating genes and pathways in these transformational changes are still largely unknown. Moreover, as a first-step toward identifying new molecular targets for the therapy of T-ALL, a powerful strategy is to clarify signaling pathways that are altered in the mouse model system and associate them with pathogenic events in human T-ALL. We therefore undertook gene set enrichment analysis (GSEA) and connectivity map (CMAP) analysis, using gene expression data from both mouse and human T-ALL cells, to identify changes in For personal use only. on November 16, 2017. by guest www.bloodjournal.org From expression profiles during distinct phases of NOTCH1-mediated T-ALL development and to gain insights into small-molecule inhibitors that would synergize with or substitute for GSIs in this disease.
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Materials and Methods
Dataset. T-ALL diagnostic specimens were collected with informed consent and approval from children treated on Children's Oncology Group-9404 in accordance with the Declaration of Helsinki.
All studies of primary human samples were approved by the Institutional Review Board. All animal studies were approved by the Institutional Animal Care and Use Committee. Genome-wide RNA expression analyses of mouse T-ALL, human T-ALL cell lines and primary samples were previously performed by us. 8, 15, 18 The datasets have been deposited in GEO database (http://www.ncbi.nlm.nih.gov/geo/); the accession numbers are GSE12948, GSE8416 and GSE14618.
Mutation detection. Sequencing of exons 28, 29 and 34 of the human NOTCH1 gene was performed on human T-ALL cell lines and primary samples at Agencourt Bioscience (Beverly, MA).
Data analysis and significant testing. After normalization by RMA algorithm, significance analysis of microarray (SAM; Stanford Univ., Stanford, CA) 19 was performed on the mouse dataset.
Differentially-expressed genes were selected based on a fold-change≥1.5 and false discovery rate~10%. Statistical significance for each gene was evaluated on the basis of the SAM score. If a gene had multiple probe sets, the one with the maximum expression was chosen for further Proteasome inhibitors MG-132 and bortezomib and a HSP90 inhibitor alvespimycin were purchased and used in this study.
Cell viability assay. Cells were plated in 96-well plates at 1 x 10 4 cells/well and treated with each of the compounds. The number of viable cells was measured by MTT assay as described previously.
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The half-maximal inhibitory concentration (IC 50 ) was calculated, and non-linear regression curves were drawn by GraphPad Prism.
Results

Transformation phases and their associated genes in a Notch1-induced mouse model of T-ALL
We previously described an intracellular Notch1 (ICN1)-induced mouse model of 8 in which polyclonal CD4 + CD8 + DP T-cells appeared at 2 weeks after transplantation of hematopoietic cells that had been transduced with the ICN1 gene (Supplemental Figure 1 ). These cells ectopically overexpressed ICN1, but had a low proliferative capacity and no tumorigenic activity, distinguishing them from both normal thymocytes and leukemic DP cells. At 6-8 weeks post-transplantation, monoclonal DP cells emerged with high levels of proliferative activity and tumorigenicity. To clarify the molecular changes induced by ICN1 transduction, we performed gene expression analysis of DP cells from three different groups of mice: 1) control DP cells infected with an empty retrovirus, 2) polyclonal DP cells from mice transplanted with ICN1-transduced bone marrow cells that appeared after 2 weeks post-transplantation, and 3) monoclonal (leukemic) DP cells from mice after 6-8 weeks post-transplantation.
To identify differentially expressed genes in DP cells from the different groups of mice, we first applied the SAM algorithm 19 to our gene expression arrays from each group of mice. The results indicate that in polyclonal DP cells, 1,261 genes were significantly upregulated and 952 were downregulated when compared with normal controls ( Figure 1A ). In leukemic DP cells, 637 genes were upregulated and 1,707 downregulated compared with polyclonal DP cells ( Figure 1B ). For the genes whose expression changed in polyclonal DP cells compared to normal controls, the degree of upregulation in a subset of genes (red dots in Figure 1A ) was much greater than the degree of downregulation in the opposite subset (green dots), whereas the reverse trend was
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From observed in the comparison of leukemic versus polyclonal DP cells ( Figure 1B ). These results indicate that transcriptional overexpression dominates in the setting of Notch1 activation in non-transformed polyclonal DP cells, while downregulation of a subset of genes predominates in the transformed leukemic cells.
A total of 4,018 genes attained significance in the analyses shown in Figure 1A and 1B (genes represented by green or red dots) and these were selected for further study (listed in Supplemental Table 2 ). To gain insights into T-ALL pathogenesis represented by these differentially expressed genes, we divided them into 8 groups based on the types of changes observed ( Figure 1C and Table 1 ). Groups 1-3 included all genes upregulated in polyclonal DP cells versus normal controls, and Groups 4-6, all genes downregulated in the same comparison.
These results were refined by subdividing the genes according to their expression patterns in leukemic versus polyclonal cells: unchanged (Groups 1 and 4); downregulated in leukemic cells (Groups 2 and 6); and upregulated in leukemic cells (Groups 3 and 5). Groups 7 and 8 included the genes that were upregulated or downregulated, respectively, in leukemic versus polyclonal DP cells but were unchanged in the comparison of polyclonal DP cells versus normal controls.
To identify the biological pathways that are deregulated in the DP cells at each phase, we then compared our mouse data with a total of 1,390 annotated gene sets using GSEA.
20,21
The significant gene sets (nominal p-value<0.05) were selected and then classified into 8 groups based on the pattern of regulation (Table 1) .
Upregulation of Notch1, Myc and other pro-survival or proliferation pathways in the polyclonal abnormal DP cells By GSEA, the gene set designated "NOTCH signaling pathway" showed the regulation For personal use only. on November 16, 2017. by guest www.bloodjournal.org From pattern of Group 2 in which Notch1 targets and co-activators were highly enriched in polyclonal DP cells compared to normal controls and were downregulated in leukemic DP cells (Figure 2A) . Most of the individual Notch1 target genes were upregulated in polyclonal DP cells but were either downregulated (Group 2: Ptcra and Snw1) or unchanged (Group 1: Dtx1 and Hes1) in leukemic DP cells ( Figure 2B ). Unlike other Notch1 targets, Myc and its target genes, such as Apex1, Nme2
and Cdk4, were classified into Group 3, with upregulation in polyclonal DP cells and even higher expression levels in leukemic DP cells ( Figure 2C ). Multiple gene sets defining the MYC pathway that include both direct transcriptional targets and interacting proteins consistently showed a high enrichment score in both polyclonal and leukemic DP cells by GSEA and the differential gene expression pattern of Group 3 ( Figure 2D ). To assess the direct targets of Notch1 and Myc, we performed GSEA using new gene sets for the recently defined direct target genes by Malgolin et al. 14 In this analysis, both the direct targets of Notch1 and Myc were classified into Group 1 (Supplemental Figure 2) . Thus, the continued upregulation of the more focused Myc targets in leukemic cells appears to be due to influence or collaborating genetic events necessary for leukemogenesis and not solely upregulation of Myc activity, which would have been reflected in the much larger number of Myc direct targets.
Besides the Notch1 and Myc pathways, GSEA identified a number of pathways that mediate cell survival, proliferation or growth that were enriched in polyclonal DP cells. For example, the JAK-STAT signaling pathway was activated in polyclonal DP cells, but then downregulated in leukemic DP cells (Group 2; Supplemental Figure 3 ). The PI3K/AKT pathway, NF-κB pathway and cell surface receptor-linked signal transduction (a category that includes cytokine signaling pathways) were upregulated in polyclonal DP cells compared with normal control (Group 1). A gene set termed "proteasome" that includes genes encoding proteasomal proteins was also upregulated in both polyclonal and leukemic DP cells (Group 1).
Downregulation of tumor suppressors and negative cell cycle regulators in the leukemic DP cells
The development of murine leukemic T-cells was characterized predominately by downregulation of tumor suppressors and negative cell cycle regulators (Group 4 or 8; Figure 3 and Table 1 ). The gene sets referred to in the GSEA program as "p53 signaling pathway" and "tumor suppressor" were downregulated specifically in leukemic DP cells compared to polyclonal DP cells (p<0.05; Figure 3A ), but were unchanged when compared in normal control versus polyclonal DP cells (Group 8). This result is consistent with our previous finding that Tp53/p53 activity was downregulated in this mouse model through downregulation of the Cdkn2a encoding ARF protein and upregulation of the Mdm2 protein.
8
In addition, the tumor suppressor Pten was downregulated in polyclonal DP cells as well as in leukemic DP cells (Group 4; Figure 3B ), while other tumor suppressors, such as Apc, Fbxw7 and Ep300, were downregulated specifically in leukemic DP cells (Group 8) . Similarly, several negative cell cycle regulators, including Rb1, Cdkn2c, Cdkn2d and Cdkn3, were specifically downregulated in leukemic DP cells (Group 8; Figure 3C ). A consistent finding in this study was that multiple gene sets related to cell cycle regulation were downregulated in leukemic DP cells compared to polyclonal DP cells, but not in polyclonal DP cells compared to normal controls (see, for example, the gene set "cell cycle arrest" in Figure 3D ). To verify the results obtained by microarray analysis, we examined mRNA and protein expression levels of Cdkn2c, Cdkn2d and Cdk4 genes in mouse DP cells (Supplemental Figure 4) . Both Cdkn2c and Cdkn2d were specifically downregulated in leukemic DP cells both at mRNA and protein levels. By For personal use only. on November 16, 2017. by guest www.bloodjournal.org From contrast, Cdk4 mRNA and protein levels were upregulated in polyclonal DP cells and further upregulated in leukemic DP cells. Taken together, these results suggest that pathways negatively regulating cell proliferation are specifically suppressed in the late phase of leukemogenesis .
Genes and pathways commonly deregulated in both mouse and human T-ALL
To assess whether the gene expression alterations we identified in our mouse model are relevant to human T-ALL, we took advantage of our previously performed gene expression profiling of human cell lines 15 and primary samples.
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For this comparison, we analyzed the profiles of
NOTCH1-active human T-ALL cells (DMSO-treated cell lines or NOTCH1-mutant primary samples)
compared with NOTCH1-inactive cells (GSI-treated cell lines or wild-type primary samples), to identify the genes that were regulated in a NOTCH1-dependent manner. In most of the human T-ALL cell lines, NOTCH1 protein is constitutively activated; 4,15 however, GSI responsiveness in terms of cell cycle arrest and growth inhibition was only observed in a fraction of these T-ALL cell lines, regardless of the NOTCH1 activation status; this resistant mechanism is in part explained by additional irreversible abnormalities such as genetic deletion or mutation of PTEN or FBXW7. 15, [24] [25] [26] We therefore used the dataset for 4 T-ALL cell lines, all of which show a high sensitivity to GSI (Supplemental Figure 5A and B), to select differentially expressed genes in GSI-treated cells versus DMSO-treated controls. Our previous work has shown that knock-down of NOTCH1 by short-hairpin RNA (shRNA) induces changes in gene expression profiles and cell phenotypes that are very similar to GSI treatment in T-ALL cell lines, 11 and that GSI phenotypic effects on T-ALL cells can be abrogated by expression of ICN1.
4,27
It is possible, however, that some aspects of the signature in GSI-treated human T-ALL cell lines could be due to effects of GSI on pathways other than those mediated downstream of NOTCH1, and work is in ongoing to identify tightly-controlled
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From conditional shRNA systems to address this issue. As shown in Figure 4A , 150 genes showed a statistically significant difference (p<0.05) in the comparison between GSI-treated cells and DMSO-treated controls. Notably, MYC and its target such as CDK4 (Group 3), and CDKN2D (Group 8) were identified by these criteria. We also compared 20 NOTCH1-mutant (MUT) primary T-ALL cases with 14 wild-type (WT) cases (see Supplemental Table 1 
GSEA and CMAP analyses implicate small-molecule inhibitors
In addition to MYC pathway, we found by GSEA that the gene set "proteasome" was highly enriched in both T-ALL cell lines and NOTCH1-mutant primary cases ( Figure 5A ), consistent For personal use only. on November 16, 2017. by guest www.bloodjournal.org From with the finding in our mouse model (Supplemental Figure 3) . This result prompted us to examine the effect of pharmacological inhibition of proteasomes in mouse and human T-ALL cells on cell growth. As shown in Figure 5B , the IC 50 values with proteasome inhibitors MG-132 and bortezomib indicated strong activities of these drugs on T-ALL cell lines as compared to the other cancer/leukemia cell lines. Interestingly, GSI-sensitive T-ALL cell lines were more sensitive to bortezomib than were GSI-resistant cell lines (p<0.05). Notably, the IC 50 value for leukemic mouse DP cells was within the range observed for the human T-ALL cell lines. MG-132 administrated with the MRK-003 GSI showed synergistic activity against the growth of GSI-sensitive T-ALL cell lines ( Figure 5C ), but not against that of GSI-resistant lines.
To discover additional therapeutic compounds that might reverse the expression of genes responsible for T-ALL pathogenesis, we performed CMAP analysis, 22 which is a pattern matching algorithm. We applied this analysis to 150 genes shown in Figure 4A (73 upregulated genes and 77 downregulated genes in GSI-treated cells versus DMSO-treated controls), which are related to the growth of leukemic cells in both mouse models and human T-ALL cell lines. We compared these shared genes that are deregulated in T-ALL with gene expression data from cultured human cells treated with bioactive small-molecule inhibitors. As shown in Table 2 , we identified 23 compounds that exhibited a strong negative correlation (p<0.001). Interestingly, multiple instances of histone deacetylase (HDAC) inhibitors, PI3K/AKT/mTOR inhibitors, and heat-shock protein 90 (HSP90) inhibitors were selected by these criteria. In particular, the expression signatures of the HDAC inhibitor vorinostat, a PI3K inhibitor LY-294002 and a HSP90 inhibitor alvespimycin showed a strong negative correlation ( Figures 6A and 7A ). The CMAP database included one instance of a proteasome inhibitor, MG-132, that also showed a negative correlation (score -0.51), but statistical
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On the strength of these results, we tested LY-294002 and vorinostat on the growth of T-ALL and other cell lines. As illustrated in Figure 6B , T-ALL cell lines were relatively more sensitive to vorinostat than were the other leukemia/cancer cell lines, and GSI-sensitive T-ALL cell lines were more sensitive to vorinostat than were the GSI-resistant cell lines (p<0.05). The reverse trend was observed when the cells were treated with LY-294002. The IC 50 value for leukemic mouse DP cells treated with vorinostat was remarkably similar to those of human T-ALL cell lines, while the mouse DP cells were more sensitive to LY-294002 than most of the T-ALL cell lines. The combination of LY-294002 with GSI inhibited GSI-resistant lines as strongly as GSI-sensitive lines ( Figure 6C ). Moreover, combination treatment with vorinostat and GSI synergistically inhibited the growth of GSI-sensitive cell lines, more strongly than GSI-resistant lines ( Figure 6D ). We also tested the HSP90 inhibitor alvespimycin that inhibited the growth of human T-ALL cell lines, regardless of GSI sensitivity ( Figure 7B ), and it did not synergize with GSI in suppressing cell growth ( Figure 7C ). The IC 50 value for leukemic mouse cells treated with alvespimycin was in the range of the most sensitive of the human T-ALL cell lines.
We examined the effects of these drugs on the cell cycle distribution of human T-ALL cell lines. In the DND41 GSI-sensitive cell line, both vorinostat-and LY-294002-treated cells exhibited a modest increase in G1-phase cells, when used in combination with GSI (Supplemental Figure 7) .
A larger increase in G1-phase population was observed in the SUP-T7 GSI-resistant cell line after the treatment with alvespimycin in combination with GSI. To identify the genes commonly targeted by all four classes of compounds, we compared the gene expression profiles in our GSI-treated T-ALL cells with the database of other cancer cells treated with these compounds. As shown in supporting the hypothesis that NOTCH1 and MYC act coordinately in T-cell transformation.
In our previous report, we demonstrated that the tumor suppressors Tp53/p53 and E2a proteins were downregulated in this mouse model. 8 Here we show that the gene sets "p53
signaling pathway" and "tumor suppressor" are downregulated in leukemic DP cells ( Figure 3A ).
Interestingly, we found that other tumor suppressors such as Apc, Fbxw7 and Ep300 were also
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From downregulated, specifically in leukemic DP cells ( Figure 3B ). APC is a negative regulator of the Wnt/β-catenin pathway, and it has been reported that this pathway is constitutively activated in T-ALL cells, 28 although deletion or mutation of the APC gene itself has not been identified in T-ALL.
Loss of APC function suppresses Notch1-dependent transcription in mice, resulting in the disruption of thymic development, 29 suggesting that these two pathways act in concert to regulate T-cell development. FBXW7 is a ubiquitin ligase that mediates the degradation of target proteins such as NOTCH1 and MYC proteins. We and others have previously reported that FBXW7 is mutated in 8.6% of primary T-ALL cases, and that dysfunction of the FBXW7 protein results in stabilization of the NOTCH1 and MYC proteins.
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EP300 encodes a histone acetyltransferase that has been reported to interact with the transcription factors such as E2A in normal thymocytes. 30 We found that the gene expression signature of T-ALL was negatively correlated with that of HDAC inhibitor-treated cells ( Figure 6A and Table 2 ) and that HDAC inhibitors exert a growth inhibitory effect on T-ALL cells ( Figure 6B ), possibly by compensating for the downregulation of EP300 in clonal leukemic DP cells in our mouse model.
We also identified the genes involved in regulation of the G1 to S cell cycle phase transition, such as Rb, Cdkn2c, Cdkn2d and Cdkn3, which are downregulated specifically in leukemic DP cells (Group 8; Figure 3C and Supplemental Figure 4 ). By contrast, Cdk4 was upregulated in both the polyclonal and leukemic DP cells in the murine model (Group3; Figure 2C and Supplemental Figure 4) . Consistently, human CDKN2D was downregulated and CDK4 was upregulated in human T-ALL cell lines and primary samples ( Figure 4A In human T-ALL, the CDKN2A gene is heterozygously or homozygously deleted in 65-90% of primary cases. [31] [32] [33] [34] [35] [36] [37] Thus, loss of function of multiple CDKN2s is a common event in both mouse model and in human T-ALL. Our gene expression analysis suggests that disruption of the G1-checkpoint through dysfunction of both the RB1 and CDKN2 proteins, and through the upregulation of CDK4, is responsible for the clonal expansion of leukemic cells in late phase of leukemogenesis and cell growth. Our recent observation supports this hypothesis, showing that the inhibition of CDK4 activity by a cyclinD1-CDK4 inhibitor (6-substituted indolocarbazole) induces growth arrest of T-ALL cell lines.
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Using GSEA and CMAP analyses, we identified proteasome inhibitors, HSP90 inhibitors, HDAC inhibitors and PI3K inhibitors as potentially useful drugs with opposing effects on the expression levels of genes deregulated by NOTCH1 in T-ALL. In fact, human T-ALL cell lines were sensitive to these inhibitors (Figures 5-7) , and importantly, the IC 50 values for mouse leukemic DP cells treated with these drugs were within the range observed for the human T-ALL cell lines, strengthening our finding that the mouse and human T-ALLs are very similar. Interestingly, the proteasome and HDAC inhibitors synergized with GSIs in suppressing cell growth of human GSI-sensitive cells. Vilimas et al have reported that the proteasome inhibitors can block NF-κB activity in T-ALL cells and synergize with the growth inhibitory effects of GSI.
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It has been reported that NF-κB is constitutively activated in many primary T-ALL cases and cell lines. Figure 8) . Because CDKN2D is downregulated in leukemic DP cells in our mouse model and is also highly upregulated after GSI treatment in human T-ALL cell lines (Figures 3 and 4) , 27 it is likely to be one of the target genes mediating the synergy between GSI and vorinostat.
In addition to proteasome inhibitors and HDAC inhibitors, PI3K/AKT/mTOR inhibitors also induced gene expression changes that were negatively correlated with the NOTCH1-induced gene expression patterns in murine and human T-ALL. Our GSEA result indicated that the PI3K pathway was already upregulated in the polyclonal DP cells in our mouse model (Supplemental Figure 3) , and that Pten, a negative regulator of PI3K/AKT pathway, was downregulated (Group 4; Figure 3B ). Hes1 is a Notch1 target gene that is upregulated in polyclonal DP cells in the murine model ( Figure 2B ) and is known to transcriptionally repress Pten expression, 14, 43 suggesting that
Pten is downregulated by Hes1 in the polyclonal phase of T-cell transformation. The PTEN gene is mutationally inactivated or deleted in many primary human T-ALL cases, 37, [43] [44] [45] indicating that loss of PTEN function is a common event in both mouse and human T-ALL. Interestingly, GSI-resistant T-ALL lines were more sensitive to a PI3K inhibitor LY-294002 than were GSI-sensitive lines ( Figure   6B ), and more importantly, this compound inhibits the growth of all T-ALL cell lines in the presence of GSI, regardless of whether the cells respond to GSI alone ( Figure 6C ), indicating that LY-294002
overcomes the resistance to GSI in T-ALL cells. Finally, several HSP90 inhibitors showed opposing effects compared to NOTCH1 on gene expression in T-ALL cells ( Figure 7A ). These inhibitors specifically block the essential ATPase activity of HSP90, a molecular chaperone for multiple signaling proteins, causing destabilization and eventual degradation of the associated client proteins that promote the growth and survival of cancer cells.
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Since we did not observe a synergy between alvespimycin and GSI ( Figure 7C ), it seems unlikely that alvespimycin is exerting its effects directly through ICN1. It does appear to provide an alternative way to target key pathways, a possibility that warrants further study in T-ALL.
In summary, we have identified interconnecting regulatory pathways at different phases of 
NOTCH1-induced
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